PTEN and melanoma: PTEN undergoes widespread functional inactivation in human cancer including GBM, melanoma, prostate adenocarcinoma (PRAD), and uterine corpus endothelial carcinoma (UCEC) through deletions, somatic mutations, and epigenetic silencing (hypermethylation of PTEN promoter) (32–36).